Contact information
Rosie Bradley
BSc, MSc
Medical Statistician
Rosie is a Medical Statistician in the Clinical Trial Service Unit (CTSU), involved in randomised trials in neurodegenerative diseases and is working on meta-analyses of breast cancer trials in Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Prior to joining in 2012, she studied Applied Statistics at the University of Plymouth (BSc) and Biometry at the University of Reading (MSc).
Recent publications
-
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) None., (2022), Lancet Oncol, 23, 382 - 392
-
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.
Early Breast Cancer Trialists’ Collaborative group (EBCTCG) None., (2021), Lancet Oncol, 22, 1139 - 1150
-
Assistive technology and telecare to maintain independent living at home for people with dementia: the ATTILA RCT.
Gathercole R. et al, (2021), Health Technol Assess, 25, 1 - 156
-
Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer’s disease: the MADE Phase II, three-arm RCT
Howard R. et al, (2020), Efficacy and Mechanism Evaluation, 7, 1 - 62
-
The impact of assistive technology on burden and psychological well-being in informal caregivers of people with dementia (ATTILA Study).
Davies A. et al, (2020), Alzheimers Dement (N Y), 6